Trial Profile
Effect of Intravenous Iron (Ferinject) on Exercise Capacity and Quality of Life of Stable COPD Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 27 Sep 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017.
- 27 Sep 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017.
- 18 Apr 2015 New trial record